Oncotarget.net features press releases on the latest oncology research, as well as interviews from the distinguished network of authors who continue to publish their research with Oncotarget.

Category: Oncotarget

Figure 1: Treatment timeline with chest computed tomography (CT) and brain magnetic resonance images (MRI) on osimertinib.

Oncotarget

Case Report: Lazarus Effect in a Patient Treated With Osimertinib for NSCLC With Leptomeningeal Disease

January 24, 2024

“[...] this case supports a body of literature noting potentially dramatic clinical benefits of administering appropriate oncogene directed targeted therapy [...]” BUFFALO, NY- January 24, 2024 – A new case… read more

Figure 1: Histological analysis of iliac crest bone biopsy.

Oncotarget

Bone Marrow Adipocytes Provide Early Sign of Progression from MGUS to Multiple Myeloma

January 22, 2024

“[...] bone marrow adipocyte density, size, and roundness are significantly different between [MGUS and MM] and could provide early signs for progression [...] to MM.” BUFFALO, NY- January 22, 2024… read more

PRESS RELEASE: On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D., published a new brief report in Oncoscience (Volume 11), entitled, “My battle with cancer. Part 1.”

Oncotarget

Dr. Blagosklonny’s Battle With Cancer (Part 1)

January 22, 2024

“Diagnosed with numerous metastases of lung cancer in my brain in January 2023, I felt compelled to accomplish a mission.” BUFFALO, NY- January 22, 2024 – On January 3, 2024,… read more

Oncotarget

ATR Inhibition Using Gartisertib in Patient-derived Glioblastoma Cell Lines

January 17, 2024

“[...] this study identifies gartisertib as a potent ATRi within patient-derived glioblastoma cell lines.” BUFFALO, NY- January 17, 2024 – A new research paper was published in Oncotarget's Volume 15… read more

Oncotarget

Reductive Carboxylation of Glutamine as a Potential Target in AML

January 16, 2024

“Identification and validation of novel and targetable metabolic weaknesses in AML is ongoing.” BUFFALO, NY- January 16, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on… read more

Oncotarget

One More Step Toward Treatment of PARP Inhibitor-resistant Ovarian Cancers

January 10, 2024

“This initiative is geared towards identifying additional biomarkers that can aid in selecting the most appropriate treatments for ovarian cancer.” BUFFALO, NY- January 10, 2024 – A new editorial paper… read more

Figure 9: One-step SARS-COv2 genome assembly in yeast S. cerevisiae using transformation-associated recombination (TAR) in yeast

Oncotarget

Transformation-associated Recombination (TAR) Cloning and Its Applications

January 8, 2024

“TAR cloning is used to genetically engineer synthetic viruses with novel properties that may be used for the development of new vaccines.” BUFFALO, NY- January 8, 2024 – A new… read more

Oncotarget

Therapeutically Harnessing Cancer Stem Cell-derived Exosomes

January 3, 2024

“[...] recent significant advances in understanding [...] CSC-Exos have revealed numerous potential applications for diagnosis and treatment.” BUFFALO, NY- January 3, 2024 – A new editorial paper was published in… read more

Figure 9: Effect of GFH009 treatment on CDK9-dependent protein expression in vivo.

Oncotarget

GFH009: A Potent and Highly Selective CDK9 Inhibitor for the Treatment of Hematologic Malignancies

December 27, 2023

“[...] the results of this preclinical investigation program suggest that induction of apoptosis is a key component of GFH009’s anti-tumor mechanism of action [...]” BUFFALO, NY- December 27, 2023 –… read more

Oncotarget

Management of Refractory or Relapsed Classic Hodgkin Lymphoma in Brazil

December 20, 2023

“The management of patients with refractory or relapsed CHL in the Brazilian healthcare setting is constrained [...]” BUFFALO, NY- December 20, 2023 – A new review paper was published in… read more